2007
Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysisEvaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
Rosenheck R. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. The British Journal Of Psychiatry 2007, 191: 238-245. PMID: 17766765, DOI: 10.1192/bjp.bp.106.035063.Peer-Reviewed Original ResearchAntipsychotic AgentsCost-Benefit AnalysisDyskinesia, Drug-InducedHumansPsychotic DisordersQuality of LifeQuality-Adjusted Life Years
2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment Outcome
1998
Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, Henderson W, Charney D. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health Services Research 1998, 33: 1237-61. PMID: 9865219, PMCID: PMC1070315.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioRefractory schizophreniaVeterans Affairs Cooperative Study GroupHigh hospital usersIncremental cost-effectiveness ratioDouble-blind trialCooperative Study GroupDisease-specific measuresVA Medical CenterStandard assessment instrumentsMeasures of symptomsMultiple outcome domainsQuality Adjusted Life YearsComposite health indexAdjusted Life YearsHealth indexStudy entryPercent confidence intervalsAverage annual costStandard treatmentCost dataRole functioningStudy groupMedical CenterSide effects